Our existing knowledge base largely derives from decades of research focused on purified proteins studied in vitro, such as β-amyloid in Alzheimer's disease or a-synuclein in Parkinson's disease, and the extent of its applicability to protein folding within the intricate microenvironment of a living cell continues to be a persistent concern. This evidence concerns the gene SNCA and Parkinson disease.